Patient group input submissions: Canagliflozin and metformin hydrochloride (Invokamet) for type 2 diabetes

Corporate Authors: Canadian Agency for Drugs and Technologies in Health, Canadian Diabetes Association, Kidney Foundation of Canada
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, 2018
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01366nam a2200337 u 4500
001 EB001872312
003 EBX01000000000000001035683
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190824 r ||| eng
245 0 0 |a Patient group input submissions: Canagliflozin and metformin hydrochloride (Invokamet) for type 2 diabetes  |h Elektronische Ressource 
246 3 1 |a Canagliflozin and metformin hydrochloride patient input submission 
246 3 1 |a Canagliflozin and metformin hydrochloride (Invokamet) for type 2 diabetes 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2018, 2018 
300 |a 1 PDF file (11 pages) 
653 |a Metformin / therapeutic use 
653 |a Patient Participation 
653 |a Canada 
653 |a Canagliflozin / therapeutic use 
653 |a Hypoglycemic Agents / therapeutic use 
653 |a Diabetes Mellitus, Type 2 / drug therapy 
653 |a Patient Satisfaction 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
710 2 |a Canadian Diabetes Association 
710 2 |a Kidney Foundation of Canada 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 |u https://www.ncbi.nlm.nih.gov/books/NBK540343  |3 Volltext 
082 0 |a 700